Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antineoplastic Agents
Carcinoma, Renal Cell
Disease-Free Survival
Double-Blind Method
Female
Humans
Kidney Neoplasms
Male
Middle Aged
Neovascularization, Pathologic
Research Design
Survival Rate
Treatment Outcome
Triazoles

authors with profiles

Mark J. Ratain
Walter M. Stadler